Enhanced anti-melanoma efficacy through a combination of the armed oncolytic adenovirus ZD55-IL-24 and immune checkpoint blockade in B16-bearing immunocompetent mouse model
| Autor: | Xiu Liang, Jing Xiao, Jinfa Gu, Ai-Min Ni, Hai-Jun Hu, Hai-Lang Li, Lanying Sun, Jin-Qing Hu, Xinyuan Liu, Huai-Yuan Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncolytic adenovirus
Cancer Research Oncolytic virus Combination therapy Tumor immune recognition medicine.medical_treatment Immunology PD-1 blockade Adenoviridae Cell Line Mice 03 medical and health sciences 0302 clinical medicine Cell Line Tumor medicine Animals Humans Immunology and Allergy Melanoma Immune Checkpoint Inhibitors 030304 developmental biology Oncolytic Virotherapy 0303 health sciences business.industry Interleukins Therapeutic effect Genetic Therapy Immunotherapy medicine.disease Combined Modality Therapy Immune checkpoint Blockade Mice Inbred C57BL Disease Models Animal Oncolytic Viruses HEK293 Cells Oncology 030220 oncology & carcinogenesis Cancer research Original Article Female business Tumor immune infiltration |
| Zdroj: | Cancer Immunology, Immunotherapy |
| ISSN: | 1432-0851 0340-7004 |
| DOI: | 10.1007/s00262-021-02946-z |
| Popis: | Although the recent treatment in melanoma through the use of anti-PD-1 immunotherapy is successful, the efficacy of this approach remains to be improved. Here, we explore the feasibility of combination strategy with the armed oncolytic adenovirus ZD55-IL-24 and PD-1 blockade. We find that combination therapy with localized ZD55-IL-24 and systemic PD-1 blockade leads to synergistic inhibition of both local and distant established tumors in B16-bearing immunocompetent mouse model. Our further mechanism investigation reveals that synergistic therapeutic effect is associated with marked promotion of tumor immune infiltration and recognition in both local and distant tumors as well as spleens. PD-1 blockade has no obvious effect on promotion of tumor immune infiltration and recognition. Localized therapy with ZD55-IL-24, however, can help PD-1 blockade to overcome the limitation of relatively low tumor immune infiltration and recognition. This study provides a rationale for investigation of such combination therapy in the clinic. Supplementary information The online version contains supplementary material available at 10.1007/s00262-021-02946-z. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink